Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
What degree of treatment related hypocalcemia would you tolerate with denosumab before switching agents?
Related Questions
Is there an evidence-based consensus on CT-derived Hounsfield unit thresholds for opportunistic assessment of osteoporosis, and how should such measurements be applied when DXA results are inconclusive or do not meet diagnostic criteria?
How do you manage hypercalcemia in an osteoporosis patient on a PTH analogue?
In cases of significant BMD loss without fractures while on long-term denosumab therapy and in the presence of very low bone turnover markers without secondary causes for bone loss, what is best approach: continuing denosumab anyway or switching to a bisphosphonate?
How soon after a fracture would it be safe to start anti-resorptive therapy?
What is the preferred osteoporosis therapy after completing teriparatide in a young woman planning pregnancy within the next year?
How would you manage a patient who has been on denosumab for 7 years and is now found to have progressive bony erosions of the external auditory canal, which the treating neurotologist suspects are secondary to denosumab?
How do you approach perioperative management of anabolic therapies such as romosozumab and PTH analogues in patients undergoing joint replacement?
Do you use bone turnover markers to assess medical adherence in patients treated for osteoporosis?
Would you consider the use of romosozumab in men who have failed therapy with teriparatide and sustained multiple vertebral fractures?
How does an incidental finding of low bone density on imaging done for another reason inform your screening approach for osteoporosis?
